Investigation of the effect of dual antithrombotic therapy with prasugrel in patients with atrial fibrillation after drug-eluting stent implantation for coronary artery disease

Investigation of the effect of dual antithrombotic therapy with prasugrel in patients with atrial fibrillation after drug-eluting stent implantation for coronary artery disease - CHIBA AF-PCI registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047503

Enrollment

400

Registered

2022-04-18

Start date

2019-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation Coronary artery disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with non-valvular atrial fibrillation requiring anticoagulant therapy. 2) patients with coronary artery disease undergoing percutaneous coronary intervention.

Exclusion criteria

Exclusion criteria: 1. PCI with two stent technique for bifurcation lesion 2. history of stent thrombosis 3. mechanical valve or bioprosthetic valve 4. cardiogenic shock 5. history of stroke, major surgery, gastrointestinal bleeding within 1 month 6. hemorrhagic disease or diathesis 7. severe renal dysfunction 8. severe lever dysfunction 9. allergy for warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, or prasugrel 10. pregnancy 11. scheduled for surgery

Design outcomes

Primary

Measure	Time frame
Major adverse cardiovascular events (all-cause death, non-fatal myocardial infarction, stent thrombosis, unplanned revascularization, stroke)	—

Countries

Japan

Contacts

Public ContactHideki Kitahara

Chiba University Graduate School of Medicine Department of Cardiovascular Medicine

hidekitahara0306@gmail.com043-222-7171

Outcome results